A Phase 2 interventional study of active repetitive transcranial magnetic stimulation and sham repetitive transcranial magnetic stimulation in Tobacco Use Disorder, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Tobacco Use Disorder by VA Office of Research and Development — 5 open to participants now, 6 under way, none of them phase 3. Tobacco Use Disorder · VA Office of Research and Development.
Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 13th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →5 of the 17 studies in Tobacco Use Disorder by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21+
VA Office of Research and Development · Sites in United States
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 50 is below the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 128 across the 16 interventional studies, 109 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
2 of the studies in Tobacco Use Disorder by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03477435VA Office of Research and DevelopmentComparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics | 2027-04-01 |
| NCT05723588VA Office of Research and DevelopmentNeuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.
Tobacco use remains the number one preventable cause of death in the United States. Unfortunately, individuals with mental health conditions are disproportionately affected. Tobacco use is also high among US Veterans, and those who have experienced trauma are even more likely to smoke. Successful quitting is especially difficult for individuals who develop posttraumatic stress disorder (PTSD). Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Neuroimaging techniques such as resting-state functional magnetic resonance imaging (rs-fMRI) have provided insight into the neurocircuitry of tobacco use disorder (TUD) and successful quit attempts. Interventions that modulate the neural systems underlying TUD, such as repetitive transcranial magnetic stimulation (rTMS), may be critical to improving clinical outcomes. Indeed, the US Food and Drug Administration (FDA) recently cleared a form of rTMS as a short-term smoking cessation treatment in adults. However, most clinical trials on rTMS for smoking cessation have been conducted in civilian samples and have excluded individuals with psychiatric conditions. To improve smoking cessation treatment options for Veterans with PTSD, it is critical to evaluate novel brain stimulation methods such as rTMS in this vulnerable population. Furthermore, the development of neuroscience-informed techniques to enhance rTMS such as neuronavigation based on rs-fMRI is critical to individualizing rTMS for smoking cessation and understanding mechanisms of action. The application of neuroimaging to develop personalized rTMS targets to precisely modulate targeted underlying neurocircuitry has been successfully applied to the treatment of major depressive disorder (MDD). Similar methodology has been demonstrated successfully for smoking cessation by the candidate's mentors, but this work was completed in a sample of civilian participants making a quit attempt who did not have psychiatric illness. To fill these knowledge gaps, the proposed research aims to develop feasibility data for the therapeutic application individualized neuronavigated rTMS for Veterans with PTSD attempting to quit smoking. Using a feasibility randomized controlled trial (RCT) design, eligible Veterans with PTSD (n=50) seeking smoking cessation will receive rs-fMRI before and after a 5-day course of neuronavigated rTMS the week prior to their quit date, in conjunction with nicotine replacement therapy (NRT) and cognitive behavioral therapy (CBT). The scientific aims of the study are to evaluate feasibility of treatment delivery procedures, develop preliminary effect size estimates, and demonstrate target engagement of the intervention within neural networks critical to TUD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has a contraindication to TMS or MRI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group will receive active repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.
Device: active repetitive transcranial magnetic stimulation · Behavioral: cognitive behavioral therapy for smoking cessation · Drug: nicotine replacement therapy
Participants assigned to this group will receive sham repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.
Device: sham repetitive transcranial magnetic stimulation · Behavioral: cognitive behavioral therapy for smoking cessation · Drug: nicotine replacement therapy
Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
Also known as: active rTMS
Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
Also known as: sham rTMS
All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
Also known as: CBT
All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a "rescue" method such as nicotine lozenge or nicotine gum.
Also known as: NRT, nicotine patch, nicotine gum, nicotine lozenges
Feasibility as measured by number of participants recruited
Number of participants recruited will serve as a measure of study feasibility. Target enrollment is 50 participants.
Time frame: At consent
Feasibility as measured by the percent of participants who complete the study
The percent of participants who complete the 3-month follow-up visit will serve as a measure of treatment feasibility. 80% retention will be the cut point.
Time frame: 3-month follow-up
Number of participants with self-reported and bioverified abstinence from smoking
Effectiveness of the intervention will be measured by the number of participants who self-report 7-day point prevalence at the end of treatment, and self-report is bioverified by exhaled carbon monoxide.
Time frame: End of treatment, about five weeks after beginning study
Number of participants with self-reported and bioverified abstinence from smoking
Effectiveness of the intervention will be measured by the number of participants who self-report 7-day point prevalence at the 3-month follow-up visit, and self-report is bioverified by salivary cotinine.
Time frame: 3-month follow-up
Average number of cigarettes smoked per day in past week
Participants will self-report the number of cigarettes they have smoked per day in the past week.
Time frame: End of treatment, about five weeks after beginning study
Average number of cigarettes smoked per day in past week
Participants will self-report the number of cigarettes they have smoked per day in the past week.
Time frame: 3-month follow-up
Self-reported withdrawal symptoms
Participants will self-report withdrawal symptoms on the Minnesota Nicotine Withdrawal Scale. Scores on this scale range from 0 to 36, with higher scores indicating higher severity of withdrawal symptoms.
Time frame: End of treatment, about five weeks after beginning study
Self-reported withdrawal symptoms
Participants will self-report withdrawal symptoms on the Minnesota Nicotine Withdrawal Scale. Scores on this scale range from 0 to 36, with higher scores indicating higher severity of withdrawal symptoms.
Time frame: 3-month follow-up
Self-report of craving based on Questionnaire of Smoking Urges
Participants will self-report cravings for tobacco on the Questionnaire of Smoking Urges. Scores on this scale range from 0 to 60, with higher scores indicating higher smoking craving.
Time frame: End of treatment, about five weeks after beginning study
Self-report of craving based on Questionnaire of Smoking Urges
Participants will self-report cravings for tobacco on the Questionnaire of Smoking Urges. Scores on this scale range from 0 to 60, with higher scores indicating higher smoking craving.
Time frame: 3-month follow-up
Number of participants who report relapse to smoking
Measured by self-report, smoking relapse is defined as smoking 5 or more cigarettes per day for 3 consecutive days.
Time frame: End of treatment, about five weeks after beginning study
Number of participants who report relapse to smoking
Measured by self-report, smoking relapse is defined as smoking 5 or more cigarettes per day for 3 consecutive days.
Time frame: 3-month follow-up
Functional network connectivity changes
Comparison of functional network connectivity (FNC) changes between the postcentral gyrus cortical rTMS target and right posterior insula using magnetic resonance imaging before and after the rTMS course
Time frame: End of repetitive transcranial magnetic stimulation treatment, about three weeks after beginning study
Neuroimaging correlates to tobacco use
Correlation of resting state functional connectivity changes pre- vs post-rTMS course and the change in the number of cigarettes smoked in the past 24 hours
Time frame: End of repetitive transcranial magnetic stimulation treatment, about three weeks after beginning study
Self-report of craving based on Urge to Smoke Scale
Participants will report smoking craving using this single-item measure. Scores range from 0 to 100 with higher scores indicating higher smoking craving.
Time frame: End of treatment visit, about five weeks after beginning study
Self-report of craving based on Urge to Smoke Scale
Participants will report smoking craving using this single-item measure. Scores range from 0 to 100 with higher scores indicating higher smoking craving.
Time frame: 3-month follow-up
Self-report of craving based on Urge to Smoke Scale
Participants will self-report craving on the single-item Urge to Smoke Scale. Scores on this scale range from 0 to 100, with higher scores indicating higher cravings to smoke.
Time frame: End of treatment, about five weeks after beginning study
Self-report of craving based on Urge to Smoke Scale
Participants will self-report craving on the single-item Urge to Smoke Scale. Scores on this scale range from 0 to 100, with higher scores indicating higher cravings to smoke.
Time frame: 3-month follow-up
Self-report posttraumatic stress disorder (PTSD) symptoms
Participants will self-report PTSD symptoms on the PTSD Checklist - 5. Scores on this measure range from 0 to 80, with higher scores indicating higher severity of PTSD symptoms.
Time frame: End of treatment, about five weeks after beginning study
Self-report posttraumatic stress disorder (PTSD) symptoms
Participants will self-report PTSD symptoms on the PTSD Checklist - 5. Scores on this measure range from 0 to 80, with higher scores indicating higher severity of PTSD symptoms.
Time frame: 3-month follow-up
Self-reported depressive symptoms
Participants will self-report depression symptoms on the Inventory of Depressive Symptomatology. Scores on this scale range from 0 to 90, with higher scores indicating higher depression symptom severity.
Time frame: End of treatment, about five weeks after beginning study
Self-reported depressive symptoms
Participants will self-report depression symptoms on the Beck Depression Inventory - 2. Scores on this scale range from 0 to 63, with higher scores indicating higher depression symptom severity.
Time frame: 3-month follow-up
Severity of baseline smoking on abstinence
Measured by self-report, plan to evaluate degree of baseline smoking severity (daily cigarettes) on smoking abstinence at end-of-treatment
Time frame: End of treatment, about five weeks after beginning study
Severity of baseline smoking on abstinence
Measured by self-report, plan to evaluate degree of baseline smoking severity (daily cigarettes) on smoking abstinence at 3-month follow-up
Time frame: 3-month follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.
Of 37 non-industry phase 2 interventional studies under Tobacco Use Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 46. This study's planned 48 months is above that.
Counting every sponsor, half of 41 studies reached it within 35 months; a quarter within 19 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →